Resultats de la cerca - David E. Allison

  • Mostrar 1 - 6 resultats de 6
Refinar resultats
  1. 1
    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial per Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina Sersch, David E. Allison

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Population pharmacokinetics of bevacizumab in cancer patients with external validation

    Population pharmacokinetics of bevacizumab in cancer patients with external validation per Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie Gosselin, Sandhya Girish, David E. Allison, Jin Jin

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer per David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, Gwen Fyfe

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... per David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Charge variants in IgG1

    Charge variants in IgG1 per Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson, Zephania W. Kwong, Jihong Yang, Xiangdan Wang, Zhenling Yao, Alavattam Sreedhara, Tony Cano, Devin B. Tesar, Ihsan Nijem, David E. Allison, Pin Yee Wong, Yung‐Hsiang Kao, Cynthia Quan, Amita Joshi, Reed J. Harris, Paul A. Motchnik

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status per Michael S. Gordon, Daniela Matei, Carol Aghajanian, Ursula A. Matulonis, Molly Brewer, Gini F. Fleming, John D. Hainsworth, Agustin A. García, Mark D. Pegram, Russell J. Schilder, David E. Cohn, Lynda D. Roman, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, David A. Eberhard, Thinh Q. Pham, Randall C. Dere, Beth Y. Karlan

    Publicat 2006
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: